Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
Kidney Research and Clinical Practice · 31.01.2023 · 42 (1) · 27-38
DOI: 10.23876/j.krcp.22.118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, erschienen am 31.01.2023. Verfasst von Yu-Hsiang Chou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Taiwan University Hospital, National Taiwan University (NTU) College of Medicine.
Abstract (Originalsprache)
Anemia is common in patients with chronic kidney disease (CKD) and is mainly caused by insufficient production of erythropoietinfrom fibrotic kidney. Because anemia impairs quality of life and overall prognosis, recombinant human erythropoietin-related products(erythropoiesis-stimulating agents, ESAs) have been developed to increase hemoglobin level for decades. However, many safety concernshave been announced regarding the use of ESAs, including an increased occurrence of cardiovascular events, vascular accessthrombosis, cancer progression, and recurrence. Hypoxia-inducible factor (HIF) is crucial to erythropoietin production, as a result, prolylhydroxylase domain (PHD) enzyme inhibitors have been new therapeutic agents for the treatment of anemia in CKD. They can beadministered orally, which is a preferred route for patients not undergoing hemodialysis. In clinical trials, PHD inhibitor could inducenoninferior effect on erythropoiesis and improve functional iron deficiency compared with ESAs. Although no serious adverse eventswere reported, safety is still a concern because HIF stabilization induced by PHD inhibitor has pleotropic effects, such as angiogenesis,metabolic change, and cell survival, which might lead to unwanted deleterious effects, including fibrosis, inflammation, cardiovascularrisk, and tumor growth. More molecular mechanisms of PHD inhibition and long-term clinical trials are needed to observe thesepleotropic effects for the confirmation of safety and efficacy of PHD inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Physiology, National Taiwan University School of Medicine, Taipei, Taiwan.
- Research Center for Developmental Biology and Regenerative Medicine, National Taiwan University, Taipei, Taiwan.
Förderung
- Ministry of Science and Technology, Taiwan
- National Taiwan University Hospital
- National Taiwan University (NTU) College of Medicine
- National Taiwan University
Zitieren
APA
Chou, Y. H., Pan, S. Y., & Lin, S. L. (2023). Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?. Kidney Research and Clinical Practice, 42(1), 27-38. https://doi.org/10.23876/j.krcp.22.118
Vancouver
Chou YH, Pan SY, Lin SL. Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?. Kidney Research and Clinical Practice. 2023;42(1):27-38. doi:10.23876/j.krcp.22.118
BibTeX
@article{Chou2023,
author = {Chou, Yu-Hsiang and Pan, Szu-Yu and Lin, Shuei-Liong},
title = {Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?},
journal = {Kidney Research and Clinical Practice},
year = {2023},
volume = {42},
number = {1},
pages = {27--38},
doi = {10.23876/j.krcp.22.118}
}
EUVIMED